Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC – Get Free Report) was the target of a significant decline in short interest during the month of October. As of October 30th, there was short interest totaling 99,181 shares, a decline of 56.7% from the October 15th total of 229,146 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 738,430 shares, the days-to-cover ratio is currently 0.1 days.
Oncotelic Therapeutics Stock Up 1.5%
Shares of OTCMKTS:OTLC traded up $0.00 during trading on Monday, hitting $0.01. 161,425 shares of the company were exchanged, compared to its average volume of 312,869. The stock has a market cap of $6.12 million, a price-to-earnings ratio of 0.02 and a beta of -0.10. Oncotelic Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.10. The firm has a fifty day moving average price of $0.02 and a two-hundred day moving average price of $0.04. The company has a current ratio of 0.08, a quick ratio of 0.08 and a debt-to-equity ratio of 0.01.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for cancer and other serious diseases. Its research includes therapies intended to affect biological pathways involved in tumor growth and the body’s immune response. The company’s lead candidate, OT-101, is an antisense therapy designed to inhibit transforming growth factor beta 2 (TGF-?2). Oncotelic has pursued its development for cancers including glioblastoma and pancreatic cancer; it remains an investigational drug, not an approved treatment.
Further Reading
- Five stocks we like better than Oncotelic Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Oncotelic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncotelic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
